Systemic Lupus Erythematous Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – AstraZeneca, Eli Lilly and Company, UCB Pharma

April 06 16:17 2023
Systemic Lupus Erythematous Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies - AstraZeneca, Eli Lilly and Company, UCB Pharma
DelveInsight’s “Systemic Lupus Erythematous Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Systemic Lupus Erythematous.

DelveInsight’s “Systemic Lupus Erythematous Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Systemic Lupus Erythematous, historical and forecasted epidemiology as well as the Systemic Lupus Erythematous market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Systemic Lupus Erythematous market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Systemic Lupus Erythematous Market Forecast

 

Some of the key facts of the Systemic Lupus Erythematous Market Report: 

  • The Systemic Lupus Erythematous market size was valued approximately USD 1,600 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • The total prevalent population of Systemic Lupus Erythematous in the 7 major markets was 658,562 in 2021

  • In the United States, in 2021, the Systemic Lupus Erythematous accounted for 355,039 prevalent cases

  • In the United States, in 2021, there were 113,612 cases of mild, 163,318 moderate and 78,108 severe Systemic Lupus Erythematous cases

  • In EU5 countries, the UK had the highest prevalent cases of Systemic Lupus Erythematous patients with 69,389  cases, followed by Germany (47,100) and Italy (43,194). In contrast, Spain had the lowest cases (36,019) in2021

  • Izmirly et al. (2021) conducted a meta-analysis of the CDC national lupus registries. The pooled prevalence of Systemic Lupus Erythematous from the four state-specific registries was 72.8 per 100,000 person-years (95% confidence interval [95% CI] 65.3–81.0)

  • As per a study by Schwarting et al. (2021), estimated Systemic Lupus Erythematous incidence between 2009 and 2014 ranged from4.59 to 6.89 per 100,000 persons, and prevalence ranged from 37.32 to 47.36 per 100,000.  incidence in Germany in 2014 was 8.82 per 100,000 persons, and prevalence was 55.80

  • The dynamics of the Systemic Lupus Erythematous market is anticipated to change in the coming years owing to the improvement in the research and development activities for efficient treatment options to be available in the market. T

  • Key Systemic Lupus Erythematous Companies: AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others

  • Key Systemic Lupus Erythematous Therapies: LY3471851, Lupuzor, BIIB059, Dapirolizumab pegol, Gazyva, Cenerimod, Medi-546, LY3471851, Belimumab, Sifalimumab, BMS-986165, Dapirolizumab pegol, Efavaleukin Alf, BOS161721, and others

  • The Systemic Lupus Erythematous epidemiology based on gender analyzed that Systemic Lupus Erythematous is more prevalent in females

  • The Systemic Lupus Erythematous market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Systemic Lupus Erythematous pipeline products will significantly revolutionize the Systemic Lupus Erythematous market dynamics.

 

Systemic Lupus Erythematous Overview

According to the American College of Rheumatology, Systemic lupus erythematous, referred to as SLE is a chronic (long-term) disease that causes systemic inflammation which affects multiple organs. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain. Many patients experience fatigue, weight loss, and fever.

 

Get a Free sample for the Systemic Lupus Erythematous Market Report –

https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-market

 

Systemic Lupus Erythematous Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Systemic Lupus Erythematous Epidemiology Segmentation:

The Systemic Lupus Erythematous market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Systemic Lupus Erythematous

  • Prevalent Cases of Systemic Lupus Erythematous by severity

  • Gender-specific Prevalence of Systemic Lupus Erythematous

  • Diagnosed Cases of Episodic and Chronic Systemic Lupus Erythematous

 

Download the report to understand which factors are driving Systemic Lupus Erythematous epidemiology trends @ Systemic Lupus Erythematous Epidemiology Forecast

 

Systemic Lupus Erythematous Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Systemic Lupus Erythematous market or expected to get launched during the study period. The analysis covers Systemic Lupus Erythematous market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Systemic Lupus Erythematous Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Systemic Lupus Erythematous Therapies and Key Companies

  • LY3471851: Eli Lilly/Nektar

  • Lupuzor: ImmuPharma

  • BIIB059: Biogen

  • Dapirolizumab pegol: UCB Pharma/ Biogen

  • Gazyva: Hoffmann-La Roche

  • Cenerimod: Idorsia

  • Medi-546: AstraZeneca

  • LY3471851: Eli Lilly and Company

  • Belimumab: GlaxoSmithKline

  • Sifalimumab: MedImmune LLC

  • BMS-986165: Bristol-Myers Squibb

  • Dapirolizumab pegol: UCB Biopharma

  • Efavaleukin Alf: Amgen

  • BOS161721: Boston Pharmaceuticals

 

Discover more about therapies set to grab major Systemic Lupus Erythematous market share @ Systemic Lupus Erythematous Treatment Market

 

Systemic Lupus Erythematous Market Drivers

  • Promising therapeutic approaches

  • Increasing awareness of the disease

  • Recent advancements in research and development

 

Systemic Lupus Erythematous Market Barriers

  • Obstacles in Systemic Lupus Erythematous pipeline

  • Hit and trial approach of researchers

  • High annual cost

 

Scope of the Systemic Lupus Erythematous Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Systemic Lupus Erythematous Companies: AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others

  • Key Systemic Lupus Erythematous Therapies: LY3471851, Lupuzor, BIIB059, Dapirolizumab pegol, Gazyva, Cenerimod, Medi-546, LY3471851, Belimumab, Sifalimumab, BMS-986165, Dapirolizumab pegol, Efavaleukin Alf, BOS161721, and others

  • Systemic Lupus Erythematous Therapeutic Assessment: Systemic Lupus Erythematous current marketed and Systemic Lupus Erythematous emerging therapies

  • Systemic Lupus Erythematous Market Dynamics: Systemic Lupus Erythematous market drivers and Systemic Lupus Erythematous market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Systemic Lupus Erythematous Unmet Needs, KOL’s views, Analyst’s views, Systemic Lupus Erythematous Market Access and Reimbursement 

 

To know more about Systemic Lupus Erythematous companies working in the treatment market, visit @ Systemic Lupus Erythematous Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Systemic Lupus Erythematous Market Report Introduction

2. Executive Summary for Systemic Lupus Erythematous

3. SWOT analysis of Systemic Lupus Erythematous

4. Systemic Lupus Erythematous Patient Share (%) Overview at a Glance

5. Systemic Lupus Erythematous Market Overview at a Glance

6. Systemic Lupus Erythematous Disease Background and Overview

7. Systemic Lupus Erythematous Epidemiology and Patient Population

8. Country-Specific Patient Population of Systemic Lupus Erythematous 

9. Systemic Lupus Erythematous Current Treatment and Medical Practices

10. Systemic Lupus Erythematous Unmet Needs

11. Systemic Lupus Erythematous Emerging Therapies

12. Systemic Lupus Erythematous Market Outlook

13. Country-Wise Systemic Lupus Erythematous Market Analysis (2019–2032)

14. Systemic Lupus Erythematous Market Access and Reimbursement of Therapies

15. Systemic Lupus Erythematous Market Drivers

16. Systemic Lupus Erythematous Market Barriers

17.  Systemic Lupus Erythematous Appendix

18. Systemic Lupus Erythematous Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

  Categories: